Abstract

BackgroundIn sub-Saharan Africa, men living with HIV often start ART at more advanced stages of disease and have higher early mortality than women. We investigated gender difference in long-term immune reconstitution.Methods/Principal FindingsAntiretroviral-naïve adults who received ART for at least 9 months in four HIV programs in sub-Saharan Africa were included. Multivariate mixed linear models were used to examine gender differences in immune reconstitution on first line ART.A total of 21,708 patients (68% women) contributed to 61,912 person-years of follow-up. At ART start,. Median CD4 at ART were 149 [IQR 85–206] for women and 125 cells/µL [IQR 63–187] for men. After the first year on ART, immune recovery was higher in women than in men, and gender-based differences increased by 20 CD4 cells/µL per year on average (95% CI 16–23; P<0.001). Up to 6 years after ART start, patients with low initial CD4 levels experienced similar gains compared to patients with high initial levels, including those with CD4>250cells/µL (difference between patients with <50 cells/µL and those with >250 was 284 cells/µL; 95% CI 272–296; LR test for interaction with time p = 0.63). Among patients with initial CD4 count of 150–200 cells/µL, women reached 500 CD4 cells after 2.4 years on ART (95% CI 2.4–2.5) and men after 4.5 years (95% CI 4.1–4.8) of ART use.ConclusionWomen achieved better long-term immune response to ART, reaching CD4 level associated with lower risks of AIDS related morbidity and mortality quicker than men.

Highlights

  • According to UNAIDS, more than 3.9 million patients were receiving antiretroviral therapy (ART) in sub-Saharan Africa at the end of 2009

  • Women achieved better long-term immune response to ART, reaching CD4 level associated with lower risks of AIDS related morbidity and mortality quicker than men

  • This study explored gender differences in immune reconstitution after the first 9 months of ART, to focus on the second phase of immune reconstitution, in four sub-Saharan African HIV programs supported by Medecins Sans Frontieres (MSF)

Read more

Summary

Introduction

According to UNAIDS, more than 3.9 million patients were receiving antiretroviral therapy (ART) in sub-Saharan Africa at the end of 2009. This represents 37% of those in need of treatment and an increase of one million patients in one year [1]. Immune recovery after ART initiation follows two phases: a rapid increase during the first months, followed by a slower one thereafter [7,8,9] They correspond to different biological mechanisms: the first phase of rapid CD4 cell increase is linked to the relapse of pre-trapped CD4 cells [10], while the second phase corresponds to a proliferation of new CD4 cells, related to thymus reactivation, which progressively reconstitutes stocks of CD4 cells [11].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call